Supernus Pharmaceuticals (NASDAQ:SUPN) Hits New 52-Week Low – Should You Sell?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)’s stock price hit a new 52-week low on Tuesday . The company traded as low as $41.05 and last traded at $41.16, with a volume of 61717 shares. The stock had previously closed at $41.49.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Wednesday, June 24th. Cantor Fitzgerald increased their price objective on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a research note on Thursday, July 9th. Wall Street Zen cut shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Zacks Research downgraded Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 4th. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $62.83.

Supernus Pharmaceuticals Stock Up 0.2%

The company has a market capitalization of $2.41 billion, a P/E ratio of -21.55, a PEG ratio of 0.76 and a beta of 0.56. The business has a 50 day simple moving average of $45.75 and a 200-day simple moving average of $47.80.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) EPS for the quarter, missing the consensus estimate of $0.42 by ($1.43). Supernus Pharmaceuticals had a positive return on equity of 11.13% and a negative net margin of 13.23%.The firm had revenue of $219.06 million for the quarter, compared to the consensus estimate of $205.31 million. During the same quarter in the prior year, the company posted $0.40 EPS. The firm’s revenue was up 32.4% on a year-over-year basis. Equities analysts forecast that Supernus Pharmaceuticals, Inc. will post 1.97 EPS for the current fiscal year.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Sit Investment Associates Inc. increased its holdings in shares of Supernus Pharmaceuticals by 0.4% in the 4th quarter. Sit Investment Associates Inc. now owns 65,200 shares of the specialty pharmaceutical company’s stock valued at $3,240,000 after purchasing an additional 250 shares during the period. Summit Global Investments boosted its holdings in shares of Supernus Pharmaceuticals by 6.1% during the first quarter. Summit Global Investments now owns 4,436 shares of the specialty pharmaceutical company’s stock worth $229,000 after purchasing an additional 256 shares during the period. PNC Financial Services Group Inc. grew its position in Supernus Pharmaceuticals by 2.3% during the first quarter. PNC Financial Services Group Inc. now owns 14,548 shares of the specialty pharmaceutical company’s stock valued at $752,000 after purchasing an additional 321 shares in the last quarter. Corient Private Wealth LP grew its position in Supernus Pharmaceuticals by 6.6% during the second quarter. Corient Private Wealth LP now owns 5,163 shares of the specialty pharmaceutical company’s stock valued at $240,000 after purchasing an additional 321 shares in the last quarter. Finally, Covestor Ltd increased its stake in Supernus Pharmaceuticals by 16.2% in the 4th quarter. Covestor Ltd now owns 2,683 shares of the specialty pharmaceutical company’s stock valued at $133,000 after buying an additional 374 shares during the period.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) disorders. The company’s portfolio addresses conditions including epilepsy, migraine and attention-deficit/hyperactivity disorder (ADHD), with an emphasis on extended-release and other drug-delivery technologies.

Supernus markets Oxtellar XR (oxcarbazepine extended-release) for the treatment of partial-onset seizures and Trokendi XR (topiramate extended-release) for certain epilepsy indications and the prevention of migraine headaches.